Nubeqa ™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer (for specialized target groups only)

Darolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyle / ARAMIS data will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on Friday, May 29, and will be available on the ASCO website
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news